

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
**WO 02/05791 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00**

(21) International Application Number: PCT/EP01/07676

(22) International Filing Date: 4 July 2001 (04.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0017635.4 18 July 2000 (18.07.2000) GB

(71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHN SPA** [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MASSIMINI, Giorgio** [IT/IT]; Via Padre Carlo Vigeveno, 26, I-20081 Abbiategrasso (IT). **PISCITELLI, Gabriella** [IT/IT]; Via Tantardini, 7, I-20136 Milan (IT). **MINARDI, Giovanni** [IT/IT]; Via Camellie, 7, I-20095 Cusano Milanino (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTITUMOR COMBINED THERAPY

(57) Abstract: A method of treating a human being suffering from a hormone-dependent disorder characterized by the overexpression of EGFR, comprising administering to said human being an aromatase inhibitor and an EGFR antagonist or EGFR inhibitor, in amounts effective to produce a superadditive or synergistic therapeutic effect.



**WO 02/05791 A2**

## ANTITUMOR COMBINED THERAPY

5 The present invention concerns the treatment of estrogen  
dependent disorders characterized by the overexpression of  
EGFR. More specifically, the invention concerns the  
treatment of a human being susceptible to or diagnosed with  
a disorder characterized by the overexpression of EGFR with  
a combination of an EGFR antagonist or inhibitor and an  
10 aromatase inhibitor.

The utility of aromatase inhibitors; EGFR antagonists and  
EGF inhibitors is well acknowledged in anticancer therapy.  
However, it is also well known in the art that  
administration to a patient of therapeutically effective  
15 amounts of aromatase inhibitors can cause considerable side  
effects. The major toxicities are for instance lethargy,  
hot flashes, rash, transient leukopenia, dizziness, nausea,  
constipation and vomiting. On the other hand, also  
administration to a patient of therapeutically effective  
20 amounts of an EGFR antagonist or inhibitor can similarly  
cause considerable side effects, e.g. hypersensitivity,  
alterations of renal function, myocardial lesions and  
cardiotoxicity in general.

25 The inventors of the present invention have found that a  
combination therapy of an hormone, in particular estrogen,  
dependent disorder characterized by the overexpression of  
EGFR, comprising a therapeutically effective amount of an  
aromatase inhibitor and a therapeutically effective amount  
30 of an EGFR antagonist or inhibitor, can produce a  
therapeutic effect which is greater than that obtainable by  
single administration of a therapeutically effective amount  
of either a sole aromatase inhibitor or a sole EGFR  
antagonist or inhibitor.

Similarly they have found that a combination therapy of an hormone, in particular estrogen, dependent disorder characterized by the overexpression of EGFR, comprising a therapeutically sub-effective amount of an aromatase inhibitor and a therapeutically sub-effective amount of an EGFR antagonist or inhibitor, can produce substantially the same therapeutic effect, which is obtainable by single administration of a therapeutically effective amount of either an aromatase inhibitor or an EGFR antagonist or inhibitor. The most important, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administrations of either therapeutically effective amounts of an aromatase inhibitor or therapeutically effective amounts of an EGFR antagonist or inhibitor.

In view of the above, the effectiveness of an aromatase inhibitor and an EGFR antagonist or inhibitor is significantly increased without a parallel increased toxicity. In other words, the combined therapy of the present invention enhances the therapeutic effects of the aromatase inhibitor and the EGFR antagonist or inhibitor and thus yields more effective and less toxic treatment for hormone-dependent disorders.

Accordingly, the present invention provides a new and valuable tool in the therapy of hormone dependent disorders characterized by the overexpression of EGFR. The advantages provided by the present invention can be appreciated by their preferred features, described herebelow.

Examples of such disorders are cancers, e.g. breast, cervical, ovarian and endometrial cancers. However a preferred example of such disorders is breast cancer in a human being, in particular a female.

Accordingly, the present invention provides, as a first object, a pharmaceutical composition comprising an aromatase inhibitor and an EGFR antagonist or inhibitor, having a synergistic or superadditive therapeutic activity  
5 against an hormone-dependent disorder characterized by the overexpression of EGFR.

The present invention also provides the use of an aromatase inhibitor in the manufacture of a pharmaceutical  
10 composition for treatment of an hormone-dependent disorder characterized by the overexpression of EGFR, the treatment additionally comprising the administration of a composition comprising an EGFR antagonist or inhibitor, in amounts effective to produce a superadditive effect.

15 Examples of aromatase inhibitors according to the invention are exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrozole, trilostane, testolactone, formestane, atamestane, 1-methyl-1,4-androstadiene-3,17-  
20 dione (MAD), ketokonazole, fadrozole, letrozole, vorozole and anastrozole.

Preferred examples of aromatase inhibitors according to the invention are exemestane, anastrozole and letrozole, in particular exemestane.

25 The aromatase inhibitors cited herein are well known products, which are cited for instance in Cancer-Treat-Res.: 94, 231-254, 1998 and WO 99/30708.

An EGFR inhibitor is for instance compound ZM 105180, compound CP 358774 or compound ZD 1839. Compound ZM 105180  
30 is 6-amino-4-(3-methylphenyl-amino)-quinazoline which is known from WO 95/03283. Compound CP 358774 is N-(3-ethylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, which is known from WO 96/30347. Compound ZD 1839 is N(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)-  
35 propoxy]4-quinazolinamine, which is known from WO 96/33980.

Alternatively, an EGFR antagonist is for instance an antibody.

An antibody against EGFR, according to the invention, can be either an "intact" antibody or a fragment thereof.

5 The term "antibody" is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit  
10 the desired biological activity. "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies; single-  
15 chain antibody molecules; and multispecific antibodies formed from antibody fragments.

An antibody against EGFR is in particular chimerized antibody C225 (cetuximab) and human antibodies E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 and E7.6.3, in particular  
20 E7.6.3. Preferred antibodies against EGFR are chimerized antibody C225 and human antibody E7.6.3. Chimerized antibody C225 is disclosed by WO 94/49210. Human antibodies E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 and E7.6.3 are disclosed by WO 98/50433.

25

The present invention also provides a product comprising an aromatase inhibitor and an EGFR antagonist or inhibitor, as combined preparation for simultaneous, separate or sequential administration, in amounts to produce a  
30 synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of EGFR.

In a further aspect, the present invention provides a kit  
35 comprising, in a suitable container means, a pharmaceutical

composition containing an aromatase inhibitor, as an active agent, and an EGFR antagonist or inhibitor, as a further active agent, in amounts to produce a synergistic or superadditive therapeutic activity against hormone-  
5 dependent disorder characterized by the overexpression of EGFR.

A further aspect of the present invention is to provide a method of treating a human being, particularly a female,  
10 suffering from an hormone-dependent disorder characterized by the overexpression of EGFR comprising administering to said human being an aromatase inhibitor and an EGFR antagonist or inhibitor, in amounts effective to produce a superadditive or synergistic therapeutic effect.

15 A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an aromatase inhibitor in a human being, particularly a female,  
20 suffering from an hormone-dependent tumor overexpressing EGFR, the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an EGFR antagonist or inhibitor, in amounts effective to produce a superadditive or synergistic  
25 antitumor effect, while controlling the growth of neoplasm formation.

A still further aspect of the present invention is to provide a method for lowering the side effects (adverse  
30 reactions) caused by antitumor therapy with an EGFR antagonist or inhibitor in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing EGFR, the method comprising administering to said human being a combined preparation comprising an EGFR  
35 antagonist or inhibitor and an aromatase inhibitor, in

amounts effective to produce a superadditive or synergistic antitumor effect, while controlling the growth of neoplasm formation.

5 The combination preparation according to the invention can also include combination packs or compositions in which the constituents are placed side by side and can be administered simultaneously, separately or sequentially to one and the same human being. Accordingly, the aromatase  
10 inhibitor and the EGFR antagonist or inhibitor may be present within a single or distinct container.

By the term "a superadditive or synergistic antitumor effect" as used herein is meant the inhibition of the  
15 growth tumor, preferably the complete regression of the tumor, by administering a combination of an aromatase inhibitor, as defined above, and an EGFR antagonist or inhibitor, to a human being, particularly a human female. Said preparation having therefore a potentiated antitumor  
20 (superadditive) activity with respect to products containing either an aromatase inhibitor or an EGFR antagonist or inhibitor, which is greater than the sum of the actions of individual components.

By the term "administered" or "administering" as used  
25 herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration. Preferably the aromatase inhibitor and the EGFR antagonist or inhibitor are administered in a sequential, separate or substantially  
30 simultaneous manner.

By "parenteral" is meant intravenous, subcutaneous, intradermal or intramuscular administration.  
Oral administration includes administering the constituents of the combined preparation in a suitable oral form such  
35 as, e.g., tablets, capsules, suspensions, solutions,

emulsions, powders, syrups and the like.

Parenteral administration includes administering the constituents of the combined preparation by subcutaneous, subcutaneous, intravenous or intramuscular injections.

5

The actual preferred method and order of administration of the combined preparations of the invention may vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the EGFR antagonist or inhibitor being utilized, the particular cancer being treated and the particular patient being treated.

The dosage ranges for the administration of the combined preparation may vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.

The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions.

In the combined method of treatment according to the subject invention, the aromatase inhibitor may be administered simultaneously with the EGFR antagonist or inhibitor or the compounds may be administered sequentially, in either order.

An effective amount of an aromatase inhibitor antitumor agent may vary from about 0.5 to about 500 mg pro dose 1-2 times a day. Exemestane, for example, may be administered orally in a dosage range varying from about 5 to about 200 mg, and particularly, from about 10 to about 25 mg, or parenterally from about 50 to about 500 mg, in particular from about 100 to about 250 mg.



Fadrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.

5 Letrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg.

Formestane, for example, may be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg.

10 Anastrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.

In the method of the subject invention, for example for the administration of the recombinant humanized monoclonal  
15 antibody anti-EGFR C225 (cetuximab), the course of therapy generally employed is from about 150 to about 500 mg/m<sup>2</sup> of body surface area. Preferably, the course therapy employed consists of a loading dose of about 400 mg/m<sup>2</sup>, followed by weekly maintenance dosage of about 180-250 mg/m<sup>2</sup>. According  
20 to a preferred embodiment of the invention patients are given an injection of cetuximab as a weekly, dose escalating 4-week protocol, with doses up to 200 mg/m<sup>2</sup>. If the disease is stabilized, then a further 8-week course can begin.

25 In the method of the subject invention, for the administration e.g. of the recombinant humanized monoclonal antibody E7.6.3 the course of therapy generally employed is from about 1 to about 1000 mg/m<sup>2</sup> of body surface area. More preferably, the course therapy employed is from about 60 to  
30 about 600 mg/m<sup>2</sup> of body surface area.

In the method of the subject invention, for the administration e.g. of compound CP-358774 the course of therapy generally employed is from about 25 to about 150 mg/day p.o.s., so that to reach a plasma concentration from  
35 about 300 to about 700 ng/ml, preferably 500 ng/ml.

In the method of the subject invention, for the administration e.g. of compound ZD 1839 the course of therapy generally employed is from about 50 to about 300 mg/day p.os.

5 The therapy method according to the present invention is, in particular, suitable for treating a human being suffering from hormone dependent disorders, characterized by the overexpression of EGFR. Typical examples of such disorders are tumors, like ovarian, cervical and  
10 endometrial cancers in a human female or breast cancer in a human being, in particular a female.

More in particular, the combined use of an aromatase inhibitor, according to the invention, preferably exemestane, and an EGFR antagonist, for example antibody  
15 C225 or E7.6.3 or an EGFR inhibitor, e.g. compounds CP-358774, ZD 1839 or ZM 105180, can be suitable for the treatment of patients with cancers over-expressing EGFR, for example, for patient with breast cancer, in particular with metastatic breast cancer, over-expressing EGFR.

20 According to a preferred aspect of the present invention the superadditive antitumor effect results in an anti breast cancer therapy having increased effectiveness in controlling, i.e. slowing, interrupting, arresting, stopping or reversing, the neoplasm formation.

25 As used herein, "controlling the growth" of the neoplasm refers to slowing, interrupting, arresting or stopping its growth and it does not necessarily indicate a total elimination of the neoplasm.

Therefore, the term "treating" simply means that the life  
30 expectancy of an individual affected with a cancer will be increased, that one or more of the symptoms of the disease will be reduced and/or that quality of life will be enhanced.

The compositions and combined therapy method of the  
35 invention provide therefore a two-way attack in particular

on cancer cell growth. Exemestane in view of its biological properties, is the most preferred example of aromatase inhibitor according to the invention.

From the pharmacological point of view, the valuable  
5 biological properties of exemestane may be found in its peculiar mechanism of aromatase inactivation.

The aromatase enzyme ( $450_{\text{arom}}$ ) is a specific form of cytochrome P450 hemoprotein composed of a P450 (heme) moiety and a peptidic moiety. The enzyme catalyzes a  
10 multistep reaction leading to aromatization of the A ring of the androgen substrate (mainly androstenedione) to estrone, requiring the presence of the cofactor NADPH. After this enzymatic reaction, the enzyme molecule is once more available to perform a new aromatization.

15 The exemestane's mechanism of aromatase inhibition has been extensively studied and the compound has been found to cause enzyme inactivation. In fact exemestane, structurally related to the natural substrate androstenedione, is initially recognized by the aromatase enzyme as a false  
20 substrate, therefore competes with androstenedione at the active site of the enzyme. The compound is then transformed (through and NADPH-dependent mechanism) to an intermediate which binds irreversibly to the enzyme causing its inactivation (also known as suicide inhibition). Therefore  
25 the enzyme is definitely inactivated and *de novo* enzyme synthesis is required for oestrogen production.

Suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are  
30 within the scope of this invention.

A pharmaceutically composition containing an aromatase inhibitor and/or an EGFR antagonist or inhibitor can be prepared according to well known techniques to those skilled in the art. For instance a pharmaceutical

composition containing exemestane can be prepared according to US 4,808,616.

CLAIMS

1. Use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for the treatment of a hormone-dependent disorder characterized by the overexpression of EGFR, wherein the pharmaceutical composition is for administration in combination therapy with a composition comprising an EGFR antagonist or an EGFR inhibitor, in amounts effective to produce a superadditive or synergistic effect.
2. Use, according to claim 1, wherein the disorder is breast, cervical, ovarian or endometrial cancer.
3. Use, according to claim 2, wherein the disorder is breast cancer.
4. Use, according to any one of the preceding claims, wherein the aromatase inhibitor is selected from exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrozole, trilostane, testolactone, formestane, atamestane, 1-methyl-1,4-androstadiene-3,17-dione (MAD), ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
5. Use, according to claim 4, wherein the aromatase inhibitor is exemestane.
6. Use, according to any one of the preceding claims, wherein the EGFR inhibitor is an antibody against EGFR.
7. Use, according to claim 6, wherein the antibody is selected from chimerized antibody C225 and human antibodies E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 and E7.6.3.

8. Use according to claim 6, wherein the antibody is selected from chimerized antibody C225 and human antibody E7.6.3.

5

9. Use, according to any one of claims 1 to 5, wherein the EGFR antagonist is selected from ZM 105180, CP-358774 and ZD 1839.

10 10. A product comprising an aromatase inhibitor and an EGFR antagonist or EGFR inhibitor, as a combined preparation for simultaneous, separate or sequential administration, in amounts effective to produce a synergistic or superadditive therapeutic effect, in the treatment of a hormone-dependent disorder characterized by the overexpression of EGFR.

11. A method of treating a human being suffering from a hormone-dependent disorder characterized by the overexpression of EGFR, said method comprising administering to said human being, simultaneously, separately or sequentially, an aromatase inhibitor and an EGFR antagonist or EGFR inhibitor, in amounts effective to produce a superadditive or synergistic therapeutic effect.

12. A method for reducing the side effects caused by the treatment of a human being suffering from a hormone-dependent tumor overexpressing EGFR, with an aromatase inhibitor, the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an EGFR antagonist or an EGFR inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect, while controlling the growth of neoplasm formation.

13. A method for reducing the side effects caused by the treatment of a human being suffering from a hormone-dependent tumor overexpressing EGFR with an EGFR antagonist or EGFR inhibitor, the method comprising administering to said human being a combined preparation comprising an EGFR antagonist or an EGFR inhibitor and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect, while controlling the growth of neoplasm formation.

14. A method according to any one of claims 11, 12 or 13 wherein the aromatase inhibitor and the EGFR antagonist or EGFR inhibitor are administered in a sequential, separate or a substantially simultaneous manner.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
**WO 02/005791 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/395**,  
A61P 35/00 // (A61K 39/395, 31:00)

(21) International Application Number: PCT/EP01/07676

(22) International Filing Date: 4 July 2001 (04.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0017635.4 18 July 2000 (18.07.2000) GB

(71) Applicant (for all designated States except US): **PHARMACIA ITALIA SPA** [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MASSIMINI, Giorgio** [IT/IT]; Via Padre Carlo Vigevano, 26, I-20081 Abbiategrasso (IT). **PISCITELLI, Gabriella** [IT/IT]; Via Tantarini, 7, I-20136 Milan (IT). **MINARDI, Giovanni** [IT/IT]; Via Camelia, 7, I-20095 Cusano Milanino (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
3 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTITUMOR COMBINATION COMPRISING AN AROMATASE INHIBITOR AND AN EGFR ANTAGONIST OR INHIBITOR

(57) Abstract: A method of treating a human being suffering from a hormone-dependent disorder characterized by the overexpression of EGFR, comprising administering to said human being an aromatase inhibitor and an EGFR antagonist or EGFR inhibitor, in amounts effective to produce a superadditive or synergistic therapeutic effect.



WO 02/005791 A3



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 01/07676**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K39/395 A61P35/00 //(A61K39/395,31:00)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, CHEM ABS Data, EMBASE, WPI Data, PAJ, EP0-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 31140 A (GENENTECH INC) 24 June 1999 (1999-06-24) page 11, line 10 - line 33; claims -----	1-4, 10-14

☐

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

14 October 2002

Date of mailing of the international search report

22/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 01/07676

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 11-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-14  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-14

Present claims 1-14 relate to a compounds defined by reference to a desirable characteristic or property, namely "aromatase inhibitor", "EGFR antagonist" and EGFR inhibitor".

The claims cover all compounds having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds individually structurally identified by name in the claims, with due regard to the therapeutic applications mentioned in the claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/07676

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9931140	A	24-06-1999	AU 1908199 A 05-07-1999
			BR 9815363 A 16-10-2001
			CA 2311409 A1 24-06-1999
			CN 1281468 T 24-01-2001
			EP 1037926 A1 27-09-2000
			JP 2002508397 T 19-03-2002
			NO 20002957 A 11-08-2000
			TR 200001689 T2 22-01-2001
			WO 9931140 A1 24-06-1999
			ZA 9811162 A 07-06-2000
-----			